Morning Market Movers
Neurocrine Biosciences (NASDAQ: NBIX) jumped 60.40% to $15.66 after the company reported positive results of VMAT2 inhibitor NBI-98854 in Kinect 2 study.
Epizyme (NASDAQ: EPZM) moved up 55.32% to $31.84 after the company reported two major milestone achievements. It announced the achievement of a proof of concept milestone in the EPZ-5676 DOT1L inhibitor clinical program.
Verso Paper (NYSE: VRS) rose 31.70% to $4.23 after the company announced its plans to acquire NewPage for $1.4 billion.
Stereotaxis (NASDAQ: STXS) shares jumped 19.26% to $4.77 after the company Stereotaxis completed the clinical trial of Vdrive with V-Loop.
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.